Search filters

List of works by Jean-Michel Molina

1284. Study of Single Nucleotide Polymorphisms Associated with HIV-1 Set-Point Viral Load in Antiretroviral Therapy-Naïve HIV-Positive Participants of the START Study

article

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

article

A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection ⬇️

scientific article published on August 1, 2013

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection ⬇️

scientific article published on April 15, 2013

A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks

scientific article published in December 2007

A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results

scientific article published on 01 May 2012

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen

scientific article published on 01 October 2006

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results

scientific article published in March 2014

A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection

scientific article

A week 48 randomized phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients

scientific article published on 19 April 2018

AIDS-Related Kaposi's Sarcoma Can Occur during Peginterferon-α and Ribavirin Therapy for Chronic Hepatitis C Infection ⬇️

scientific article published on September 20, 2011

About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE.

scientific article published on 7 June 2007

Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France

scientific article published on 15 November 2011

Acute Guillain-Barré syndrome during the chronic phase of HIV infection and dramatic improvement under highly active antiretroviral therapy

scientific article published on 01 July 2002

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine

scientific article published on 25 September 2020

Acute fever in an immunocompromised patient

scientific article

Acute fever in an immunocompromised patient

scientific article published on 01 November 2015

Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial

scientific article published on 11 February 2020

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

scientific article

An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe

scientific article published in May 2010

Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully

scientific article published on 01 November 2003

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel

scientific article published on 01 July 2018

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel

scientific article published on 14 October 2020

Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study

scientific article published on 26 June 2016

Antiretroviral Therapy Initiation in France

article

Antiretroviral switch studies do matter

scientific article published on 08 October 2018

Aseptic meningitis associated with intravenous administration of dexchlorpheniramine

scientific article published in May 2003

Assessment of HIV Screening Tests for Use in Preexposure Prophylaxis Programs

scientific article published on 27 June 2017

Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia

scientific article published on 20 May 2014

Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial

scientific article published on 01 September 2019

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

scientific article published on 20 January 2015

Becoming adherent to a preventive treatment for HIV: a qualitative approach

scientific article published on 11 July 2019

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures

article

Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic Review

scientific article

Bladder cancer in HIV-infected adults: an emerging concern?

scientific article

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

scientific article published in PLoS ONE

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard fir

scientific article published in November 2016

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regime

scientific article published on 01 October 2019

Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with HIV.

scientific article published in July 2010

Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults

scientific article

Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? ⬇️

scientific article published on August 23, 2013

Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis

scientific article published on 01 February 2020

Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy

scientific article published on 01 January 2007

Characterization of Binding of Raltegravir to Plasma Proteins ⬇️

scientific article published on July 15, 2013

Characterization of HIV-1 diversity in various compartments at the time of primary infection by ultradeep sequencing

scientific article published on 12 February 2020

Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient

scientific article published on 16 September 2009

Clinical characteristics, risk factors, and outcome of tuberculosis in kidney transplant recipients: A multicentric case-control study in a low-endemic area

scientific article published on 28 June 2018

Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study

scientific article

Clinically relevant genotype interpretation of resistance to didanosine

scientific article

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

scientific article published on June 30, 2012

Community-Based Care in the ANRS-IPERGAY Trial: The Challenges of Combination Prevention

scientific article published on 01 June 2019

Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays

scientific article

Comparison of A60 and three glycolipid antigens in an ELISA test for tuberculosis

scientific article published on 01 February 1996

Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.

scientific article published in January 2005

Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients

scientific article published on January 2008

Complement C5 inhibition in patients with COVID-19 - a promising target?

scientific article published on 23 July 2020

Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition

scientific article

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

scientific article published on 9 October 2015

Correlates of poor perceived health among individuals living with HIV and HBV chronic infections: a longitudinal assessment

article

Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components

scientific article published on 29 August 2016

Costs and benefits of on-demand HIV preexposure prophylaxis in MSM.

scientific article

Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 Window Trial

scientific article published on December 2008

Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial

scientific article published on 29 April 2020

Covid-19 related IgA vasculitis

scientific article published on 06 July 2020

Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France

scientific article published on 01 September 2018

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

scientific article published on 29 August 2019

Decreases in Inflammatory and Coagulation Biomarkers Levels in HIV-Infected Patients Switching from Enfuvirtide to Raltegravir: ANRS 138 Substudy ⬇️

scientific article published on June 24, 2013

Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay

scientific article

Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stool specimens from immunocompromised patients with intestinal microsporidiosis

scientific article published on 15 April 2003

Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial

scientific article

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

scientific article

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

scientific article published on 23 March 2018

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

scientific article published on 15 November 2019

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferi

scientific article published on 18 December 2020

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

scientific article published on 01 February 2019

Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections

scientific article published on 01 March 2020

Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial

article

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study

scientific article published in 2019

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-author

scientific article published on 20 September 2020

Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial.

scientific article published on 2 November 2014

Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis

scientific article published on 01 January 2020

Early diagnosis and risk factors of acute hepatitis c in high-risk men who have sex with men on pre-exposure prophylaxis

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV‐Infected Subjects: Week 48 Data from the Altair Study ⬇️

scientific article published on October 1, 2010

Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial

Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV ⬇️

scientific article published on March 27, 2012

Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).

scientific article published on January 2008

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hep

scientific article published on 20 January 2017

Effects of chemical and physical agents on viability and infectivity of Encephalitozoon intestinalis determined by cell culture and flow cytometry

scientific article published on June 2002

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

scientific article published on 01 December 2019

Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy

article

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

scientific article published on 16 February 2017

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

scientific article

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

scientific article published on July 2004

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

scientific article published on January 2010

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

scientific article published in November 2009

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study ⬇️

scientific article published on October 18, 2011

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial

scientific article

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

scientific article published in May 2012

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically

scientific article published on 5 October 2017

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicent

scientific article published on 18 June 2018

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial

scientific article published on 9 January 2018

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

scientific article

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

scientific article

Emerging and Reemerging Sexually Transmitted Infections

scientific article published on 01 August 2020

Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia

scientific article published on March 2011

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

scientific article published on 01 July 2020

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment

scientific article published on 16 March 2009

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy

scientific article published on 5 May 2016

Evaluation of drug abuse by hair analysis and self-reported use among MSM under PrEP: Results from a French sub-study of the ANRS-IPERGAY trial

scientific article published on 23 December 2020

Factors associated with partner notification of STIs in men who have sex with men on PrEP in France: a cross-sectional substudy of the ANRS-IPERGAY trial

scientific article published on 29 January 2018

Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon

scientific article published on 2 April 2008

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).

scientific article published in January 2007

Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study

scientific article published on 25 March 2020

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

scientific article published on 10 June 2009

Fosfomycin-trometamol (FT) or fluoroquinolone (FQ), as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): a prospective cohort study

scientific article published on 28 October 2020

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

scientific article published on 01 March 2020

Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial) ⬇️

scientific article published on October 28, 2010

Fumagillin treatment of intestinal microsporidiosis

scientific article (publication date: 20 June 2002)

Genetically intact but functionally impaired HIV-1 Env glycoproteins in the T-cell reservoir.

scientific article published on 29 November 2017

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials

scientific article published on 13 October 2008

HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.

scientific article published in January 2008

HLA-B*5701 screening for hypersensitivity to abacavir

scientific article

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals

article

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.

scientific article

Hepatitis A infections in men who have sex with men using HIV PrEP in Paris

scientific article published on 11 January 2018

Hepatitis Rebound after Infection with Yellow Fever Virus

scientific article published in June 2019

Herpes Simplex Virus Type 2 as a Cause of Severe Meningitis in Immunocompromised Adults ⬇️

scientific article published on November 6, 2003

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study

scientific article published on 14 May 2015

High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men who Have Sex with Men. A Sub-Study of the ANRS Ipergay PrEP Trial

scientific article published on 11 December 2020

High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial

scientific article

High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients

scientific article published on 18 April 2013

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response

scientific article published on 8 March 2015

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).

scientific article published on September 2016

Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients

article

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

scientific article published on 01 November 2007

Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.

scientific article published in January 2006

Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy

scientific article published on 11 January 2020

Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus

scientific article published in November 2007

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

scientific article

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations

scientific article

Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).

scientific article published on September 2010

Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir

scientific article

In-depth Sampling of High-risk Populations to Characterize HIV Transmission Epidemics Among Young MSM Using PrEP in France and Quebec

article

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial

scientific article published on 2 April 2016

Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial

scientific article

Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit

scientific article published on 06 December 2018

Infectious Zika virus in vaginal secretions from an HIV-infected woman, France, August 2016.

scientific article published on January 2017

Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy

scientific article

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial

scientific article

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

scientific article

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial

scientific article published on 18 February 2015

Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).

scientific article published on July 2009

Intermittent antiretroviral therapy in patients with controlled HIV infection

scientific article

Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data

scientific article

Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort

scientific article published on 22 July 2015

Is on-Demand HIV Pre-exposure Prophylaxis a Suitable Tool for Men Who Have Sex With Men Who Practice Chemsex? Results From a Substudy of the ANRS-IPERGAY Trial

scientific article published on 01 October 2018

JC virus variant associated with cerebellar atrophy in a patient with AIDS.

scientific article

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial

article

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

La prévention pré-exposition au VIH-1 par les antirétroviraux, la PrEP

scientific article published on 01 June 2016

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL

scientific article published on 01 April 2019

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.

scientific article published on 12 October 2016

Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.

scientific article published on January 2010

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial

scientific article published on 01 April 2012

Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation

scientific article published on 7 January 2014

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

scientific article published on 16 August 2010

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

scientific article published on 01 August 2018

Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV.

scientific article published in February 2006

Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial

scientific article published on 27 April 2017

Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure

scientific article

Mortality of People Living with HIV in Paris Area from 2011 to 2015

scientific article published on 05 November 2019

Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era.

scientific article published on March 2017

Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection

scientific article published on 01 May 2018

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibit

scientific article published in July 2009

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

scientific article

On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial

scientific article published on 26 November 2019

Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis

scientific article published on 01 March 2020

Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis

scientific article published on 01 March 2020

Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies

scientific article published on January 2003

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

scientific article published in March 2010

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

scientific article published in August 2008

Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study

scientific article published on 12 November 2018

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO

scientific article published on 2 November 2014

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

scientific article published on 10 March 2015

Pandemic Influenza A (H1N1) Infection among HIV-Infected Adults in France ⬇️

scientific article published on May 12, 2011

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial

scientific article published on 27 August 2018

Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir

scientific article published on 01 December 2018

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

scientific article published in September 2008

Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients

scientific article published on 20 March 2009

Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection

scientific article published on 25 November 2020

Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users' ambivalences

scientific article published on 19 March 2020

Pharmacogenetics of Toxicity, Plasma Trough Concentration and Treatment Outcome with Nevirapine-Containing Regimen in Anti-Retroviral-Naïve HIV-Infected Adults: An Exploratory Study of the TRIANON ANRS 081 Trial ⬇️

scientific article published on 06 September 2011

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

scientific article published on 01 August 2018

Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study

scientific article published on 3 July 2014

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study ⬇️

scientific article published on November 25, 2011

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy

scientific article published on 23 June 2015

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients ⬇️

scientific article published on October 23, 2010

Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results.

scientific article published on 4 October 2017

Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection

scientific article published on 21 December 2006

Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the N

scientific article published in March 2020

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial

scientific article published on 8 December 2017

Pre-exposure prophylaxis of HIV infection

scientific article published on October 2014

Presence of Lamivudine or Emtricitabine Is Associated with Reduced Emergence of Nonnucleoside Reverse Transcriptase Inhibitor Mutations in an Efavirenz-Based Intermittent Antiretroviral Treatment Regimen ⬇️

scientific article published on December 27, 2011

Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles

scientific article published on 17 July 2013

Prevalence and incidence of HPV infection in men having sex with men enrolled in a PrEP study: A sub-study of the ANRS IPERGAY trial

scientific article published on 07 January 2020

Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised

scientific article published on 30 January 2012

Prevalence of opportunistic intestinal parasitic infections among HIV-infected patients with low CD4 cells counts in France in the combination antiretroviral therapy era.

scientific article published on 6 July 2012

Prioritisation of subgroups for immediate antiretroviral therapy - Authors' reply

scientific article published on 01 May 2018

Prognostic Factors and Outcome of Human Herpesvirus 8–Associated Primary Effusion Lymphoma in Patients With AIDS

article

Quality of Travel Health Advice in a French Travel Medicine and Vaccine Center: A Prospective Observational Study ⬇️

scientific article published on February 24, 2012

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

article

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

scientific article published on 11 September 2017

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir

scientific article

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

scientific article published on 9 April 2014

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection

scientific article published in 2015

Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects ⬇️

scientific article published on July 1, 2013

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen

scientific article published on 01 August 2019

Reactivation of HBV replication in HIV-HBV infected patients.

scientific article

Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis

scientific article published in June 2010

Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study.

scientific article

Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen

scientific article published on 01 July 2003

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy

scientific article published in January 2018

Remission of disseminated infection caused by Encephalocytozoon intestinalis with highly active antiretroviral therapy

scientific article published on 01 March 2003

Remission of severe CD8(+) cytotoxic T cell skin infiltrative disease in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy

scientific article published in September 2010

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen ⬇️

scientific article published on November 13, 2010

Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART.

scientific article published in October 2008

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

scientific article published in July 2011

Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.

scientific article published in January 2007

Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era.

scientific article published on 27 March 2014

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

scientific article published on 4 August 2014

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

scientific article

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients

scientific article published on 24 January 2002

SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4

scientific article

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients

scientific article published on 17 February 2017

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.

scientific article published on 28 July 2014

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

scientific article published in September 2007

Safety and efficacy of fumagillin for the treatment of intestinal microsporidiosis. A French prospective cohort study

scientific article published on 30 October 2020

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study

scientific article published on 01 November 2020

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial

scientific article

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

scientific article published in PLoS ONE

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

scientific article

Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada.

scientific article

Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype

scientific article (publication date: 2017)

Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting

scientific article

Severe Actinobacillus ureae meningitis in an immunocompromised patient: report of one case and review of the literature

scientific article published on 06 August 2007

Severe Acute Renal Failure in an HIV-Infected Patient After Only 2 Weeks of Tenofovir-Based Antiretroviral Therapy ⬇️

scientific article published on July 13, 2011

Severe Peripheral Neuropathy Following HAART Initiation in an HIV-Infected Patient With Leprosy ⬇️

scientific article published on July 1, 2010

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial

scientific article published on 10 February 2005

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial

scientific article published on 28 September 2016

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

scientific article published on 4 February 2015

Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial

scientific article published in November 2005

Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era.

scientific article

Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a Pharmacokinetic Substudy of the EASIER-ANRS 138 Trial ⬇️

scientific article published on May 16, 2011

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

scientific article published in October 2009

Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial

scientific article published on 28 July 2008

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b,

scientific article published on March 2017

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

scientific article published on 01 August 2019

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation

scientific article published on 10 December 2020

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled

scientific article published on 18 June 2018

Telaprevir enhances ribavirin-induced anaemia through renal function impairment

scientific article published on 6 January 2014

Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial

scientific article

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial

scientific article published on 17 December 2015

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

scientific article published on 15 April 2015

Tenofovir disoproxil fumarate-induced Fanconi's syndrome during HIV postexposure prophylaxis

scientific article published in May 2016

Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus

scientific article published on 4 April 2003

The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the “participant”-physician relationship

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

scientific article published on February 2016

The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: A randomized controlled trial ⬇️

scientific article published on June 22, 2013

The maraviroc expanded access program - safety and efficacy data from an open-label study

scientific article

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen ⬇️

scientific article published on September 24, 2010

Topical imiquimod for recurrent acyclovir-resistant HSV infection

scientific article published on 01 May 2006

Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients

scientific article published in April 2005

Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status

scientific article published in PLoS ONE

Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia

scientific article published on 01 November 2018

Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial

scientific article published on 17 February 2016

Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099

scientific article published on 04 May 2006

Varicella pneumonia in an immunocompetent adult

scientific article published on 09 May 2013

Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adults

scientific article published on 4 May 2011

Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial

article

Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (

scientific article published on 4 October 2017

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients ⬇️

scientific article published on April 24, 2011

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

article

What are the situational and behavioral factors associated with condomless anal sex without PrEP in men who have sex with men? Results from the ANRS-IPERGAY trial

scientific article published on 13 April 2020

Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial

scientific article published on 15 January 2018

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

scientific article

Paulina is supported by:

About Paulina

Help